贝伐单抗抑制角膜移植术后新生血管及免疫排斥反应的作用

doi:10.13281/j.cnki.issn.1004-4469.2017.02.008

眼科

贝伐单抗抑制角膜移植术后新生血管及免疫排斥反应的作用

李坤王平武珅张敬学刘谦李纳

100730 首都医科大学附属北京同仁医院北京同仁眼科中心北京市眼科研究所眼科学与视觉科学北京市重点实验室

收稿日期:2016-11-21 出版日期:2017-03-25 发布日期:2017-03-29
通讯作者: 李纳，Email: wmzina@hotmail.com

Effect of bevacizumab on corneal neovascularization and immune rejection after corneal transplantation

LI Kun, WANG Ping, WU Shen, ZHANG Jing-xue, LIU Qian, LI Na

Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology and Visual Science, Beijing 100730, China

Received:2016-11-21 Online:2017-03-25 Published:2017-03-29
Contact: LI Na, Email: wmzina@hotmail.com

摘要/Abstract

摘要：

目的探讨贝伐单抗对同种异体角膜移植术后免疫排斥反应的影响，评价其对角膜植片存活的疗效及作用机制。设计实验研究。研究对象 近交系F344大鼠15只为供体，近交系Lewis大鼠30只为受体。方法受体大鼠右眼行穿透性角膜移植术后随机数字法分为3组：对照组（A组）、贝伐单抗组（B组）、地塞米松组（C组），每组10只。B、C组分别于术后0、3、6、9天结膜下注射40 μl贝伐单抗注射液及20 μl地塞米松磷酸钠注射液；A组不做处理。术后裂隙灯下观察14天，记录排斥指数（RI，为植片水肿、混浊、新生血管长入评分合计）和新生血管侵袭面积（IA）。术后14天，采用免疫荧光法检测角膜植片中CD4+、CD8+免疫细胞的表达。主要指标 角膜新生血管面积，免疫排斥时间，免疫细胞的数量。结果术后7天IA分别为：A组（22.50±3.67）mm2，B组（14.21±2.79）mm2，C组（15.38±0.84）mm2；A组明显多于B组及C组（P=0.00和0.01），B组与C组无显著差异（P=0.059）。术后14天IA分别为：A组（27.96±0.50）mm2，B组（18.76±2.73）mm2，C组（23.74±2.14）mm2。A组及C组多于B组（P=0.000）。免疫排斥时间A组8天，B组11天，C组13天。B组及C组角膜植片存活时间均长于A组（P均=0.000）。免疫细胞： CD4+阳性细胞数：A组（13.2±2.94）个，B组（6.14±1.07）个，C组（3.5±1.78）个；CD8+阳性细胞数：A组（14.4±2.44）个，B组（4.5±1.51）个，C组（3.38±1.68）个。术后14天，B组、C组角膜植片中CD4+、CD8+细胞亦明显少于A组（P均=0.000）。结论结膜下注射贝伐单抗可有效抑制大鼠同种异体穿透性角膜移植术后新生血管的生长，并可能通过此作用延缓移植排斥反应，延长角膜植片存活时间。但贝伐单抗抗移植排斥反应疗效略逊于地塞米松。（眼科，2017, 26： 101-105）

关键词: 贝伐单抗, 角膜移植, 移植物排斥, 大鼠

Abstract:

Objective To investigate the effects of bevacizumab on prevention of corneal neovascularization in a rat model of penetrating keratoplasty, and to evaluate its effect on the survival of corneal grafts. Design Experimental studies. Participants Fifteen F344 rats were used as donor and 30 Lewis rats as recipients. Methods After penetrating keratoplasty, recipients were randomly divided into three groups: control group(GA), bevacizumab group (GB) and dexamethasone group (GC). A single dose of 40 μl bevacizumab was injected subconjunctivally in GB at 0, 3, 6 and 9 days after operation. GC were subconjunctivally injected with 20 μl dexamethasone. GA was not treated. Grafts were examined every three day for two weeks by slit-lamp biomicroscopy, the rejection index (RI, edema, opacity, neovessels) and neovessel invasion area (IA) were calculated. After 14 days, the rats were killed and the expression of CD4+ and CD8+ cells in corneal grafts was detected by immunofluorescence. Main Outcome Measures Neovessel invasion area, grafts survival time and cell counting of CD4+ and CD8+. Results Seven days after surgery, IA in GA differed significantly from GB (P=0.00) and GC (P=0.01) , but GB and GC were closed to each other. At Day 7, IA was 22.50±3.67mm2(GA), 14.21±2.79mm2 (GB) and 15.38±0.84mm2(GC) respectively; at Day 14, IA was 27.96±0.50mm2(GA), 18.76±2.73mm2 (GB) and 23.74±2.14mm2(GC) respectively. The corneal grafts survival in GB and GC was longer than GA (all P=0.000). The corneal grafts survival was 8(GA), 11(GB),13(GC) days respectively. At Day 14, the CD4+, CD8+ cells in GA were higher than GB and GC (all P=0.000). The number of CD4+ cells was 13.2±2.94(GA), 6.14±1.07(GB) and 3.5±1.78(GC) respectively. The number of CD8+ cells was 14.4±2.44(GA), 4.5±1.51(GB) and 3.38±1.68(GC) respectively. Conclusions Subconjunctival administration of bevacizumab may effectively inhibit neovascularization and corneal graft rejection. But bevacizumab is less effective than dexamethasone on inhibiting corneal allograft rejection. (Ophthalmol CHN, 2017, 26: 101-105)

Key words: bevacizumab, penetrating keratoplasty, rejection, rat

李坤王平武珅张敬学刘谦李纳 . 贝伐单抗抑制角膜移植术后新生血管及免疫排斥反应的作用[J]. 眼科, doi: 10.13281/j.cnki.issn.1004-4469.2017.02.008.

LI Kun, WANG Ping, WU Shen, ZHANG Jing-xue, LIU Qian, LI Na. Effect of bevacizumab on corneal neovascularization and immune rejection after corneal transplantation[J]. Ophthalmology in China, doi: 10.13281/j.cnki.issn.1004-4469.2017.02.008.

[1]	骆非接英胡健萍张晓昭李丽潘志强. HLA-A/B、DR抗原的基因配型对穿透性角膜移植免疫排斥反应影响的研究[J]. 眼科, 2022, 31(4): 297-301.
[2]	余婷肖格格彭荣梅洪晶. 434例儿童角膜移植患者的疾病构成分析[J]. 眼科, 2022, 31(2): 98-103.
[3]	李晨迪冯云洪晶. 角膜移植手术患者术前结膜囊细菌培养菌群分布及影响因素研究[J]. 眼科, 2021, 30(2): 131-135.
[4]	李上卢红双臧云晓张薇董宏伟郭纯刚潘志强接英. 脱细胞猪角膜基质作为植片的深板层角膜移植治疗感染性角膜溃疡的临床观察[J]. 眼科, 2018, 27(3): 164-170.
[5]	张樱楠梁庆丰刘洋苗森张敬王立潘志强. 12岁以下儿童穿透性角膜移植手术的临床分析[J]. 眼科, 2017, 26(4): 262-266.
[6]	周晓晴魏锐利. 翼状胬肉治疗中应用贝伐单抗的疗效的Meta分析[J]. 眼科, 2016, 25(3): 175-180.
[7]	郝静华骆非闫超潘志强 . 穿透性角膜移植术后继发青光眼的疗效分析[J]. 眼科, 2014, 23(6): 392-397.
[8]	李绍伟陈铁红刘畅宁建华吕芳奇曹丽娜赵宁. 角膜内皮移植治疗穿透性角膜移植术后植片失代偿的长期疗效观察[J]. 眼科, 2014, 23(3): 170-173.
[9]	李丹麻南罗玲高付林赵军仇长宇白凤华胡莲娜. 首选玻璃体腔注射贝伐单抗或曲安奈德对比治疗视网膜中央静脉阻塞继发黄斑水肿疗效及安全性差异的荟萃分析[J]. 眼科, 2013, 22(3): 180-184.
[10]	接英潘志强. 穿透性角膜移植术后免疫抑制剂的合理应用[J]. 眼科, 2013, 22(3): 145-146.
[11]	张樱楠, 闫超, 王立, 刘静, 潘志强. 不同种族角膜植片对穿透性角膜移植术效果的影响[J]. 眼科, 2013, 22(2): 98-100.
[12]	麻南李丹高付林赵宏伟白凤华胡莲娜 . 首选玻璃体腔注射贝伐单抗与曲安奈德对比治疗视网膜分支静脉阻塞继发黄斑水肿疗效及安全性差异的荟萃分析[J]. 眼科, 2013, 22(1): 62-66.
[13]	颜繁诚李树宁刘克高卢清君王宁利 . 大鼠视神经部分切断模型的建立和重复性评价[J]. 眼科, 2013, 22(1): 34-37.
[14]	胡健艳, 吴强, 宋蓓雯, 贾丽丽, 陈永东, 严良. 大鼠视网膜微血管内皮细胞的原代培养及鉴定改进[J]. 眼科, 2012, 21(4): 261-263.
[15]	张海娟, 马科, 游玉霞, 吴雁, 徐清　. 环孢素A纳米粒滴眼液抑制大鼠高危角膜移植免疫排斥反应的实验研究[J]. 眼科, 2012, 21(2): 116-120.

贝伐单抗抑制角膜移植术后新生血管及免疫排斥反应的作用

Effect of bevacizumab on corneal neovascularization and immune rejection after corneal transplantation

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价